Our Focus

Improving lives of patients facing challenges associated with injectable therapies for their rare or chronic diseases.

Our Mission

Chiasma develops and commercializes oral therapies

utilizing its proprietary Transient Permeability Enhancer (TPE®) technology to reduce the burden of chronic injections for people with rare diseases.

Learn More

Our Values

Persistence

We never give up. Resiliency is in our DNA.

Passion for Results

We love what we do, and we achieve results that matter for patients, for investors and for ourselves.

Ingenuity

We are clever and resourceful in how we identify and execute on meaningful opportunities.

Commitment to People

Our commitment to patients is unwavering. The only way to succeed is to commit to achieving our purpose.

Sense of Urgency

Diseases progress and our patients cannot wait. This drives us to bring innovations to market as fast as we can.

WHAT DRIVES US

Our Foundation

Our proprietary Transient Permeability Enhancer (TPE®)

technology is designed to convert select peptide based injectables into oral formulations. By leveraging this technology, patients may be alleviated of the burdens associated with chronic injectable therapies.

Our Technology

Latest News

Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021

March 22, 2021

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

March 20, 2021

Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

March 10, 2021